Deblitane

Quick links to important sections

Deblitane

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deblitane

Quick Facts

Property Description
Active ingredient Norethisterone (Norethindrone)
Form Tablet (Oral dosage form)
Pharmacological class Progestin-only Oral Contraceptive (POC)
Common use Pregnancy Prevention (Contraception)
Origin Synthetic steroid hormone

What Type of Medicine is Deblitane?

Deblitane is a prescription-only pharmaceutical preparation classified as a Progestin-only Oral Contraceptive (POC), commonly recognized as the mini-pill. This medication is designed specifically for daily birth control management in women of reproductive age. It is delivered as a yellow tablet, which is an oral dosage form for systemic administration. POCs are considered suitable for individuals who have medical contraindications to estrogen, such as a history of thromboembolic events or who are currently breastfeeding. This positions the mini-pill as a specialized alternative within hormonal birth control options.


Deblitane's Composition and Single Active Ingredient

The sole active ingredient in this single-ingredient product is Norethisterone (INN), also identified as Norethindrone. This compound is a synthetic steroid hormone that functions as a progestogen, binding to hormone receptors to effect contraceptive change. Unlike combination pills, Deblitane is a monophasic formulation that contains only the progestin, ensuring a consistent hormonal dose daily. This specific progestin-only composition provides a targeted approach to managing fertility and is categorized for oral contraceptive use.


General Purpose: Why is Deblitane Used?

The overarching general purpose of Deblitane is pregnancy prevention (contraception). Progestin-only regimens are used as a daily form of birth control and intended for consistent use. This medication achieves its goal primarily through physiological action at the cervical and uterine levels, allowing women to manage their fertility while avoiding the estrogenic component present in other oral contraceptives.

Regulatory References

  1. FDA Labeling (DailyMed/NIH)

What side effects are possible with Deblitane?

Possible Side Effects and Safety Information

The safety profile for this medicine, which contains norethindrone, is strictly based on official prescribing information, defining both common adverse reactions and absolute restrictions for use. The effects are categorized by frequency and affected body system, consistent with regulatory practices.

Frequency-Classified Adverse Reactions

Classification Examples (From Regulatory Documents)
Most Common (ge 2%) Headache, Nausea, Vaginal Candidiasis, Breast Tenderness/Pain, Acne, Weight Gain, Mood Swings.
Common Irregular Genital Bleeding (spotting, breakthrough bleeding, amenorrhea).

Serious Adverse Reactions and Contraindications

The regulatory label documents conditions that prohibit use. The use of progestin-only contraceptives is associated with a risk of ectopic pregnancy. The medication is strictly contraindicated in women with known or suspected pregnancy, carcinoma of the breast, or benign or malignant liver tumors.

System-Organ Classes and Safety Constraints

Adverse reactions commonly affect the Reproductive System (bleeding changes, menstrual cramps) and the Nervous System (headache, dizziness). For specific populations, the medicine is generally considered an appropriate contraceptive option for women who are nursing. Use is prohibited in individuals with undiagnosed abnormal genital bleeding or acute liver disease.

The official safety profile structures risk by distinguishing between frequent, non-serious events and absolute medical conditions that prevent the medicine’s use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory classification for an overdose of Deblitane (Norethindrone) establishes that the event is not expected to be life-threatening. This assessment is based on reports that state serious ill effects are very unlikely to occur following the acute ingestion of large doses of this medication. The regulatory data also includes a note that serious consequences have not been documented following acute ingestion by young children.

Documented Manifestations and Management

Regulatory documents confirm that overdose manifestations are typically limited to non-serious effects. These may include nausea and withdrawal bleeding or heavy vaginal bleeding in females. Management for overdose is officially symptomatic and supportive, as no specific antidote for Norethindrone is documented in the official prescribing information.

Mandatory Emergency Action

Government health guidance mandates specific steps for suspected overdose. Immediate action requires contacting the Poison Help hotline (1-800-222-1222 in the US) for expert instructions. Urgent intervention is required if the clinical presentation includes severe signs. Regulatory guidance explicitly states that emergency services (such as 911) must be called immediately if the person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. These conditions represent the regulator-defined triggers for seeking immediate, life-saving medical attention.

Therapeutic Uses of Deblitane

What Deblitane Treats: Main Uses and Benefits


The fundamental function of this medicine, which contains norethindrone, is commonly used for managing the risk of unplanned pregnancy (contraception) for women of reproductive age. This class of medication is indicated for the prevention of pregnancy and is generally known as the mini-pill. This progestin-only option is particularly relevant in clinical settings where patients are generally recommended to avoid estrogen, such as in cases of a history of blood clots or high blood pressure, as well as during the postpartum and breastfeeding period.

Therapeutic Support

The medication also helps manage manifestations like excessive or prolonged flow, and is relevant for easing distress associated with these symptom clusters. It is applied in addressing symptom clusters related to heightened physiological activity within the gynecologic domain, including abnormal uterine bleeding and secondary amenorrhea.

Quick Fact: Relief for Estrogen Avoidance
Common Scenarios: Used for fertility management in nursing mothers and women with estrogen sensitivities.
Primary Benefit: Provides supportive therapeutic benefit without the estrogen component of combined pills.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Deblitane — Official Regulatory Information

The following statements reflect the population eligibility and non-eligibility rules for Deblitane (Norethindrone), as strictly defined in official regulatory documents, such as FDA Prescribing Information and SmPC equivalents.


Section Details
Populations for whom use is allowed: Females of reproductive potential for pregnancy prevention. Use is generally acceptable and often preferred for nursing mothers [(DailyMed)].
Populations for whom use is contraindicated: Individuals with Known or suspected pregnancy, Known or suspected carcinoma of the breast, Undiagnosed abnormal genital bleeding, Benign or malignant liver tumors, or Acute liver disease [(DailyMed)].
Age-related eligibility rules: Use is not indicated before menarche (onset of menstruation).
Condition-specific eligibility rules: Must be used with careful monitoring in diabetic women due to potential changes in glucose tolerance. Use requires caution in patients with conditions aggravated by fluid retention, such as cardiac or renal dysfunction [(SmPC Equivalent)].
Eligibility-related restrictions: Discontinuation is required upon the onset or exacerbation of migraine or the development of severe headaches. A history of ectopic pregnancy need not be considered a contraindication to use [(DailyMed)].

Official eligibility statements:

  • Use is contraindicated in women with a history of breast cancer or active liver disease.
  • The drug is intended for females of reproductive potential and is prohibited if pregnancy is suspected.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Deblitane's efficacy can be significantly reduced when co-administered with certain other medicines, medicinal product classes, or herbal products. This primarily results from interactions that increase the metabolism of the contraceptive steroid, leading to lower concentrations in the body.

Documented Interacting Categories

Category Examples or Classification Practical Implication
Enzyme Inducers Rifamycins (e.g., Rifampin), certain Anticonvulsants (e.g., Phenytoin, Carbamazepine, Barbiturates), St. John's Wort Use of these agents may reduce contraceptive effectiveness and necessitate a supplemental or alternative contraceptive method. This requirement may extend for several weeks after discontinuation of the interacting drug.
HIV/Hepatitis C Drugs Certain Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors May cause significant, sometimes unpredictable, changes (both increases and decreases) in the progestin’s plasma levels, potentially compromising contraceptive efficacy.

Deblitane may also affect the metabolism of other co-administered drugs, potentially increasing their systemic concentration. An example of this is the documented effect on Cyclosporine, requiring careful monitoring. Additionally, this oral contraceptive can interfere with the results of certain endocrine and liver function laboratory tests, such as causing a decrease in Thyroxine concentrations due to changes in binding globulins. Prediabetic and diabetic patients should be monitored as progestin-only contraceptives may impair glucose tolerance and reduce the effect of antidiabetic agents.

Mechanism of Action

Deblitane acts as a non-competitive inhibitor of the P-450 CYP3A4 enzyme system. This specific binding mechanism suppresses the enzyme's catalytic capacity for substrate processing, reducing its overall function within the cell. Inhibition of this enzyme system results in a reduction of substrate hormone bioavailability. This subsequent decrease in substrate concentration limits the molecules’ ability to bind to target tissues, effectively preventing specific hormonal receptor agonism. The overall molecular effect is a significant alteration in the ratio of signaling molecules, which contributes to the modulation of the endocrine feedback loop via the targeted pathway. The entire process focuses on modifying the intracellular processes responsible for hormonal signaling initiation.

Dosage and Administration Information

How Deblitane is Used: Administration Guidelines

Deblitane, containing norethindrone 0.35 mg, is administered as an oral tablet for continuous, long-term use in fertility management. The established usage pattern is defined by a continuous daily regimen that dictates the administration and adherence protocols.


Standard Dosing and Schedule

The standard adult dose is one 0.35 mg tablet taken once daily. This regimen requires continuous administration; a new 28-day pack is started immediately after the last tablet of the previous pack, without any break.

Administration Constraint Detail
Timing Requirement Taken at the exact same time every day.
Food Relation May be taken without regard to meals.

Procedural Instructions and Adherence

The effectiveness of this medication is dependent on adherence to the schedule. Standard protocols include specific procedural steps for managing deviations in timing.

If a dose is taken more than 3 hours late or if a pill is missed, the protocol involves taking the dose as soon as it is remembered. Furthermore, a backup non-hormonal contraceptive method is used for the following 48 hours. This step serves as the corrective action for adherence failure. For new users, if the regimen is not started on the first day of the menstrual period, the same 48-hour backup rule applies.

Population-Specific Use

The 0.35 mg once-daily regimen is used for postpubertal adolescents. For women in the postpartum period who are fully breastfeeding, initiation of this medication is typically advised starting six weeks after delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deblitane

Evidence for use in Pregnancy Prevention (Contraception)

The evidence base for Norethindrone, the active ingredient in Deblitane, includes clinical efficacy trials submitted to regulatory bodies to measure contraceptive failure rates (Pearl Index). Large-scale observational studies track long-term use patterns and continuation rates. Studies reported measurements of contraceptive failure rates and patterns of menstrual bleeding characteristics. Reported outcomes suggest that adherence to a consistent daily administration schedule was an observation noted in the research findings.

Evidence for other Gynecologic Outcomes

The active ingredient has also been evaluated in research exploring outcomes related to Abnormal Uterine Bleeding (AUB) and pain related to Endometriosis. This research often takes the form of Randomized Controlled Trials and interventional studies that assessed outcomes such as the change in bleeding days and changes in pain scores. However, a primary limitation is that most evidence supporting this use is derived from studies using a higher-dose formulation of the active ingredient, which provides limited direct information for the low-dose contraceptive product (Deblitane).

Long-term Use and Population Data

Research has explored the outcomes of longer-term use through large epidemiological studies that track patterns over multiple years. Specific research has been evaluated in populations generally advised to avoid the estrogen component, such as breastfeeding women. While these studies provide context, long-term effects are not fully established regarding the durability of certain biological changes. Data for certain complex subgroups remains insufficient.

What the Research Indicates is Still Unclear

The evidence highlights what has been explored and where further information is needed regarding the research base. A key limitation noted in the research is the dose difference; much of the data regarding gynecologic symptom management is based on a higher-dose formulation, meaning the applicability to the low-dose contraceptive is not fully established. Additionally, study results apply only to the populations studied, and comparative evidence against certain alternative treatments is lacking.

Key Studies & References

  1. Label: NORETHINDRONE tablet - DailyMed - NIH (Contraceptive efficacy, failure rates, mechanism, adherence requirements)
  2. Progestogen-only contraceptive use among breastfeeding women: a systematic review - CDC Stacks (Evidence on no negative effects on breastfeeding performance)
  3. Drospirenone vs norethindrone progestin-only pills. Is there a clear winner? - MDEdge (Comparative efficacy and mechanism of action/ovulation inhibition)

Frequently Asked Questions (FAQ)

Common questions about Deblitane (FAQ)

Q: Are changes in mood or anxiety listed as potential side effects of Deblitane?

Official product information lists mood swings, nervousness, and depression as potential psychiatric effects. If a person experiences a change in mood or emotional state while taking this medicine, it is described as a possible side effect. You can find more detail on this in the 'Possible side effects and safety information' section.

Q: What are the severe side effects that official documents warn users about?

The official warnings section describes the possibility of serious medical events. These include the risk of ectopic pregnancy and the potential development of ovarian cysts, which rarely require surgery. Warnings also cover the risks of blood clots, severe allergic reactions, and changes in vision.

Q: Are there any specific foods or drinks that should be avoided while taking this medicine?

According to the official product information, Deblitane may be taken with or without food. Furthermore, official documents indicate that this medication is not known to interact with alcohol.

Q: Is it true that certain antibiotics can reduce the effectiveness of Deblitane?

Yes, the effectiveness of Deblitane may be reduced if taken alongside certain other medications. This includes some antibiotics, antifungal medicine, and drugs used to treat tuberculosis. The reduction in effectiveness is due to how these interacting drugs affect the hormone’s metabolism.

Q: Can individuals with a history of cardiovascular issues use Deblitane?

Regulatory documents indicate that use of this medication may require caution in individuals with a history of heart disease. Similarly, caution is advised for those with conditions, such as kidney disease, that are known to be aggravated by fluid retention.

Q: What are the major formulation differences between Deblitane and similar drugs in its class?

Deblitane is specifically classified as a Progestin-Only Pill (POP), sometimes called a mini-pill. This means its formulation contains only the progestin hormone. This distinguishes it from other forms of oral contraceptives that contain both progestin and estrogen hormones.

Q: What does the Deblitane pill look like (color, shape, markings)?

The tablet is generally described as being yellow. While the basic appearance is consistent, the exact shape and any markings may vary based on the specific generic brand prescribed. This information is fully detailed in the patient information leaflet that comes with the specific product packaging.

Q: Can the mechanism of Deblitane's action be explained in very simple, non-technical terms?

In simple terms, the medicine works in a few different ways. It primarily causes changes to the cervical mucus, which helps block sperm from entering the uterus. It also alters the lining of the uterus (endometrium). In some cases, it may also partially suppress the release of an egg, known as ovulation.

Q: Does the official information mention hair loss or acne as possible side effects?

Yes, the official safety profile lists both Acne and loss or thinning of the hair as potential side effects. These are classified among the adverse reactions described in the prescribing information.

Q: Can over-the-counter pain relievers like ibuprofen be taken with Deblitane?

According to drug interaction information, there are no known major interactions reported specifically between common over-the-counter pain relievers like ibuprofen and this medication. Official guidelines recommend consultation with a healthcare provider before taking any new medication or supplement.

Q: How quickly does Deblitane start to provide its intended effect?

Regulatory instructions establish the necessary initial procedure for use. If the pill is not started on the first day of a woman's menstrual period, a non-hormonal backup method is required for the following 48 hours as a supplementary measure, as established by regulatory instructions.

Q: What is the general guidance if a dose of Deblitane is missed by a few hours?

Official guidance establishes the required steps for missed doses. If a delay is less than 3 hours, the necessary procedure is to take the dose as soon as it is recalled. Only delays of more than 3 hours require the use of backup contraception.

Q: Does Deblitane increase the general risk of blood clots compared to no medication?

Official medical literature indicates that oral progestin-only contraceptives are associated with minimal or no thrombotic risk (risk of blood clots) when compared to other types of hormonal contraceptives. This is why this medication is often preferred for individuals who have reasons to avoid estrogen.

Q: Is there a universally recognized generic version of Deblitane available?

Yes, the generic name for Deblitane is Norethindrone at the 0.35 mg dose. This generic form is widely available and often manufactured under several different brand names depending on the market.

Q: What is the specific warning about smoking cigarettes while using Deblitane?

Official warnings state that the use of this medication is contraindicated in individuals who smoke cigarettes. This is because smoking is described as significantly increasing the risk of serious cardiovascular events, such as a heart attack, stroke, or blood clots.

Q: Can a high fever or stomach flu potentially affect how well Deblitane works?

Gastrointestinal issues such as vomiting or diarrhea are known to interfere with the body's ability to absorb oral medications fully. If this occurs, it may reduce the effectiveness of the medication.

Q: Do all users experience the same common side effects from Deblitane?

Regulatory documents classify side effects by their frequency, such as Most Common or Common. This categorization indicates that not all users will experience the same side effects, and the incidence of adverse reactions varies among individuals.

Q: What kind of healthcare provider is usually authorized to prescribe Deblitane?

Deblitane is classified as a prescription-only medication. As an authorized medication, it requires a prescription from a licensed healthcare provider, such as a doctor, nurse practitioner, or physician assistant.

Q: Are there any driving or alertness restrictions mentioned on the Deblitane label?

Official documents list side effects that affect the nervous system, including dizziness and drowsiness. Official safety information notes that caution may be advised when performing activities requiring full alertness.

Q: Is a pregnancy test a standard procedure before starting a new pack of Deblitane?

Pregnancy is explicitly listed as a contraindication for using this medication. Since pregnancy is a contraindication, the medication must be stopped immediately if pregnancy is suspected, and clinical guidance must be sought.

Q: Are there any known side effects of Deblitane that impact vision or eye health?

Official warnings state that if a user experiences blurred vision, difficulty with reading, or any change in vision, clinical guidance is required immediately. Additionally, discomfort wearing contact lenses is listed among the possible side effects.

Q: Does Deblitane have a specific coating or inactive ingredients that can cause allergic reactions?

The official prescribing information states that patients with a known allergy to any of the tablet's ingredients (active or inactive) must not use the medication. The complete list of ingredients can be requested from a pharmacist or prescribing physician.

How should Deblitane be stored and disposed of?

How to Store and Dispose of Deblitane

Deblitane (norethindrone tablets) must be stored at Controlled Room Temperature between 20 C and 25 C (68 F to 77 F), with permitted excursions up to 30 C. To maintain product stability, the tablets must be protected from both light and moisture and should remain in the original container until use.

Child Safety

It is an official requirement to keep this and all medication strictly out of the reach of children.

Disposal Instructions

Unused or expired Deblitane should be discarded using a drug take-back program if one is available locally. If a take-back option is not accessible, the product should be disposed of in the household trash only after being mixed with an unappealing substance, placed in a sealed container, and sealed to prevent accidental ingestion, following official regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deblitane found in:

A-Z Index: